Loading…
4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA
Replacement of the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA series by a 4-methyl-1,2,4-triazol-3-yl group gave us compounds with similar structure-activity relationship profiles showing that this triazole is potentially a good surrogate to imidazole for farnesyltra...
Saved in:
| Published in: | Bioorganic & medicinal chemistry letters 2003-12, Vol.13 (24), p.4361-4364 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c329t-6cb7640e6699c6fa3851105ae6d0f651c8bd0d3bda1c443669f909d5551c8e693 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c329t-6cb7640e6699c6fa3851105ae6d0f651c8bd0d3bda1c443669f909d5551c8e693 |
| container_end_page | 4364 |
| container_issue | 24 |
| container_start_page | 4361 |
| container_title | Bioorganic & medicinal chemistry letters |
| container_volume | 13 |
| creator | ANGIBAUD, Patrick SAHA, Ashis K PONCELET, Virginie ROUX, Bruno SMETS, Gerda VAN DUN, Jacky VENET, Marc WOUTERS, Walter BOURDREZ, Xavier END, David W FREYNE, Eddy LEZOURET, Patricia MANNENS, Geert MEVELLEC, Laurence MEYER, Christophe PILATTE, Isabelle |
| description | Replacement of the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA series by a 4-methyl-1,2,4-triazol-3-yl group gave us compounds with similar structure-activity relationship profiles showing that this triazole is potentially a good surrogate to imidazole for farnesyltransferase inhibition. |
| doi_str_mv | 10.1016/j.bmcl.2003.09.043 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71421760</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71421760</sourcerecordid><originalsourceid>FETCH-LOGICAL-c329t-6cb7640e6699c6fa3851105ae6d0f651c8bd0d3bda1c443669f909d5551c8e693</originalsourceid><addsrcrecordid>eNpFkUFr3DAUhEVpaTZp_0APRZf2FDlPlqy1jktIm0KaQJpC6UXI8jOrRbZTSVtwfkN_dO3NQk4P3nwzhxlCPnAoOHB1sSua3oWiBBAF6AKkeEVWXCrJhITqNVmBVsBqLX-dkNOUdgBcgpRvyckCCVGqFfkn2XfM2ykwfl6eS5ajt09jYIJNgW4xYxzd5AJSm6gdqA3zZ7DZ_0WaR5q3SDnrDwG-9-3BWi3WfvSYJ-qHA9PZOGCaQo52SB1Gm3CWtr7xeYz09-b-9urHw_3mHXnT2ZDw_fGekZ9frh4ur9nN3ddvl5sb5kSpM1OuWSsJqJTWTnVW1BXnUFlULXSq4q5uWmhF01rupBQz1mnQbVUtEiotzsjn59zHOP7ZY8qm98lhCHbAcZ_MmsuSrxXMYPkMujimFLEzj9H3Nk6Gg1k2MDuzbGCWDQxoM28wmz4e0_dNj-2L5Vj6DHw6AjY5G7q5FOfTC1cJqNe1EP8BwZaQuA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71421760</pqid></control><display><type>article</type><title>4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>ANGIBAUD, Patrick ; SAHA, Ashis K ; PONCELET, Virginie ; ROUX, Bruno ; SMETS, Gerda ; VAN DUN, Jacky ; VENET, Marc ; WOUTERS, Walter ; BOURDREZ, Xavier ; END, David W ; FREYNE, Eddy ; LEZOURET, Patricia ; MANNENS, Geert ; MEVELLEC, Laurence ; MEYER, Christophe ; PILATTE, Isabelle</creator><creatorcontrib>ANGIBAUD, Patrick ; SAHA, Ashis K ; PONCELET, Virginie ; ROUX, Bruno ; SMETS, Gerda ; VAN DUN, Jacky ; VENET, Marc ; WOUTERS, Walter ; BOURDREZ, Xavier ; END, David W ; FREYNE, Eddy ; LEZOURET, Patricia ; MANNENS, Geert ; MEVELLEC, Laurence ; MEYER, Christophe ; PILATTE, Isabelle</creatorcontrib><description>Replacement of the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA series by a 4-methyl-1,2,4-triazol-3-yl group gave us compounds with similar structure-activity relationship profiles showing that this triazole is potentially a good surrogate to imidazole for farnesyltransferase inhibition.</description><identifier>ISSN: 0960-894X</identifier><identifier>EISSN: 1464-3405</identifier><identifier>DOI: 10.1016/j.bmcl.2003.09.043</identifier><identifier>PMID: 14643326</identifier><language>eng</language><publisher>Oxford: Elsevier</publisher><subject>Administration, Oral ; Alkyl and Aryl Transferases - antagonists & inhibitors ; Animals ; Antineoplastic agents ; Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; Cell Division - drug effects ; Enzyme Inhibitors - administration & dosage ; Enzyme Inhibitors - chemical synthesis ; Enzyme Inhibitors - chemistry ; Enzyme Inhibitors - pharmacology ; Farnesyltranstransferase ; General aspects ; Heterocyclic Compounds - administration & dosage ; Heterocyclic Compounds - chemical synthesis ; Heterocyclic Compounds - chemistry ; Heterocyclic Compounds - pharmacology ; Humans ; Kinetics ; Medical sciences ; Mice ; Microsomes, Liver - drug effects ; Microsomes, Liver - metabolism ; Models, Molecular ; Molecular Conformation ; Pharmacology. Drug treatments ; Quinolones - administration & dosage ; Quinolones - chemical synthesis ; Quinolones - pharmacology ; Structure-Activity Relationship ; Triazoles - chemical synthesis ; Triazoles - chemistry ; Triazoles - pharmacology</subject><ispartof>Bioorganic & medicinal chemistry letters, 2003-12, Vol.13 (24), p.4361-4364</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c329t-6cb7640e6699c6fa3851105ae6d0f651c8bd0d3bda1c443669f909d5551c8e693</citedby><cites>FETCH-LOGICAL-c329t-6cb7640e6699c6fa3851105ae6d0f651c8bd0d3bda1c443669f909d5551c8e693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15308783$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14643326$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ANGIBAUD, Patrick</creatorcontrib><creatorcontrib>SAHA, Ashis K</creatorcontrib><creatorcontrib>PONCELET, Virginie</creatorcontrib><creatorcontrib>ROUX, Bruno</creatorcontrib><creatorcontrib>SMETS, Gerda</creatorcontrib><creatorcontrib>VAN DUN, Jacky</creatorcontrib><creatorcontrib>VENET, Marc</creatorcontrib><creatorcontrib>WOUTERS, Walter</creatorcontrib><creatorcontrib>BOURDREZ, Xavier</creatorcontrib><creatorcontrib>END, David W</creatorcontrib><creatorcontrib>FREYNE, Eddy</creatorcontrib><creatorcontrib>LEZOURET, Patricia</creatorcontrib><creatorcontrib>MANNENS, Geert</creatorcontrib><creatorcontrib>MEVELLEC, Laurence</creatorcontrib><creatorcontrib>MEYER, Christophe</creatorcontrib><creatorcontrib>PILATTE, Isabelle</creatorcontrib><title>4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA</title><title>Bioorganic & medicinal chemistry letters</title><addtitle>Bioorg Med Chem Lett</addtitle><description>Replacement of the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA series by a 4-methyl-1,2,4-triazol-3-yl group gave us compounds with similar structure-activity relationship profiles showing that this triazole is potentially a good surrogate to imidazole for farnesyltransferase inhibition.</description><subject>Administration, Oral</subject><subject>Alkyl and Aryl Transferases - antagonists & inhibitors</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cell Division - drug effects</subject><subject>Enzyme Inhibitors - administration & dosage</subject><subject>Enzyme Inhibitors - chemical synthesis</subject><subject>Enzyme Inhibitors - chemistry</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Farnesyltranstransferase</subject><subject>General aspects</subject><subject>Heterocyclic Compounds - administration & dosage</subject><subject>Heterocyclic Compounds - chemical synthesis</subject><subject>Heterocyclic Compounds - chemistry</subject><subject>Heterocyclic Compounds - pharmacology</subject><subject>Humans</subject><subject>Kinetics</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Microsomes, Liver - drug effects</subject><subject>Microsomes, Liver - metabolism</subject><subject>Models, Molecular</subject><subject>Molecular Conformation</subject><subject>Pharmacology. Drug treatments</subject><subject>Quinolones - administration & dosage</subject><subject>Quinolones - chemical synthesis</subject><subject>Quinolones - pharmacology</subject><subject>Structure-Activity Relationship</subject><subject>Triazoles - chemical synthesis</subject><subject>Triazoles - chemistry</subject><subject>Triazoles - pharmacology</subject><issn>0960-894X</issn><issn>1464-3405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpFkUFr3DAUhEVpaTZp_0APRZf2FDlPlqy1jktIm0KaQJpC6UXI8jOrRbZTSVtwfkN_dO3NQk4P3nwzhxlCPnAoOHB1sSua3oWiBBAF6AKkeEVWXCrJhITqNVmBVsBqLX-dkNOUdgBcgpRvyckCCVGqFfkn2XfM2ykwfl6eS5ajt09jYIJNgW4xYxzd5AJSm6gdqA3zZ7DZ_0WaR5q3SDnrDwG-9-3BWi3WfvSYJ-qHA9PZOGCaQo52SB1Gm3CWtr7xeYz09-b-9urHw_3mHXnT2ZDw_fGekZ9frh4ur9nN3ddvl5sb5kSpM1OuWSsJqJTWTnVW1BXnUFlULXSq4q5uWmhF01rupBQz1mnQbVUtEiotzsjn59zHOP7ZY8qm98lhCHbAcZ_MmsuSrxXMYPkMujimFLEzj9H3Nk6Gg1k2MDuzbGCWDQxoM28wmz4e0_dNj-2L5Vj6DHw6AjY5G7q5FOfTC1cJqNe1EP8BwZaQuA</recordid><startdate>20031215</startdate><enddate>20031215</enddate><creator>ANGIBAUD, Patrick</creator><creator>SAHA, Ashis K</creator><creator>PONCELET, Virginie</creator><creator>ROUX, Bruno</creator><creator>SMETS, Gerda</creator><creator>VAN DUN, Jacky</creator><creator>VENET, Marc</creator><creator>WOUTERS, Walter</creator><creator>BOURDREZ, Xavier</creator><creator>END, David W</creator><creator>FREYNE, Eddy</creator><creator>LEZOURET, Patricia</creator><creator>MANNENS, Geert</creator><creator>MEVELLEC, Laurence</creator><creator>MEYER, Christophe</creator><creator>PILATTE, Isabelle</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20031215</creationdate><title>4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA</title><author>ANGIBAUD, Patrick ; SAHA, Ashis K ; PONCELET, Virginie ; ROUX, Bruno ; SMETS, Gerda ; VAN DUN, Jacky ; VENET, Marc ; WOUTERS, Walter ; BOURDREZ, Xavier ; END, David W ; FREYNE, Eddy ; LEZOURET, Patricia ; MANNENS, Geert ; MEVELLEC, Laurence ; MEYER, Christophe ; PILATTE, Isabelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c329t-6cb7640e6699c6fa3851105ae6d0f651c8bd0d3bda1c443669f909d5551c8e693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Administration, Oral</topic><topic>Alkyl and Aryl Transferases - antagonists & inhibitors</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cell Division - drug effects</topic><topic>Enzyme Inhibitors - administration & dosage</topic><topic>Enzyme Inhibitors - chemical synthesis</topic><topic>Enzyme Inhibitors - chemistry</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Farnesyltranstransferase</topic><topic>General aspects</topic><topic>Heterocyclic Compounds - administration & dosage</topic><topic>Heterocyclic Compounds - chemical synthesis</topic><topic>Heterocyclic Compounds - chemistry</topic><topic>Heterocyclic Compounds - pharmacology</topic><topic>Humans</topic><topic>Kinetics</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Microsomes, Liver - drug effects</topic><topic>Microsomes, Liver - metabolism</topic><topic>Models, Molecular</topic><topic>Molecular Conformation</topic><topic>Pharmacology. Drug treatments</topic><topic>Quinolones - administration & dosage</topic><topic>Quinolones - chemical synthesis</topic><topic>Quinolones - pharmacology</topic><topic>Structure-Activity Relationship</topic><topic>Triazoles - chemical synthesis</topic><topic>Triazoles - chemistry</topic><topic>Triazoles - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ANGIBAUD, Patrick</creatorcontrib><creatorcontrib>SAHA, Ashis K</creatorcontrib><creatorcontrib>PONCELET, Virginie</creatorcontrib><creatorcontrib>ROUX, Bruno</creatorcontrib><creatorcontrib>SMETS, Gerda</creatorcontrib><creatorcontrib>VAN DUN, Jacky</creatorcontrib><creatorcontrib>VENET, Marc</creatorcontrib><creatorcontrib>WOUTERS, Walter</creatorcontrib><creatorcontrib>BOURDREZ, Xavier</creatorcontrib><creatorcontrib>END, David W</creatorcontrib><creatorcontrib>FREYNE, Eddy</creatorcontrib><creatorcontrib>LEZOURET, Patricia</creatorcontrib><creatorcontrib>MANNENS, Geert</creatorcontrib><creatorcontrib>MEVELLEC, Laurence</creatorcontrib><creatorcontrib>MEYER, Christophe</creatorcontrib><creatorcontrib>PILATTE, Isabelle</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic & medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ANGIBAUD, Patrick</au><au>SAHA, Ashis K</au><au>PONCELET, Virginie</au><au>ROUX, Bruno</au><au>SMETS, Gerda</au><au>VAN DUN, Jacky</au><au>VENET, Marc</au><au>WOUTERS, Walter</au><au>BOURDREZ, Xavier</au><au>END, David W</au><au>FREYNE, Eddy</au><au>LEZOURET, Patricia</au><au>MANNENS, Geert</au><au>MEVELLEC, Laurence</au><au>MEYER, Christophe</au><au>PILATTE, Isabelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA</atitle><jtitle>Bioorganic & medicinal chemistry letters</jtitle><addtitle>Bioorg Med Chem Lett</addtitle><date>2003-12-15</date><risdate>2003</risdate><volume>13</volume><issue>24</issue><spage>4361</spage><epage>4364</epage><pages>4361-4364</pages><issn>0960-894X</issn><eissn>1464-3405</eissn><abstract>Replacement of the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA series by a 4-methyl-1,2,4-triazol-3-yl group gave us compounds with similar structure-activity relationship profiles showing that this triazole is potentially a good surrogate to imidazole for farnesyltransferase inhibition.</abstract><cop>Oxford</cop><pub>Elsevier</pub><pmid>14643326</pmid><doi>10.1016/j.bmcl.2003.09.043</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-894X |
| ispartof | Bioorganic & medicinal chemistry letters, 2003-12, Vol.13 (24), p.4361-4364 |
| issn | 0960-894X 1464-3405 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71421760 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Administration, Oral Alkyl and Aryl Transferases - antagonists & inhibitors Animals Antineoplastic agents Antineoplastic Agents - chemical synthesis Antineoplastic Agents - pharmacology Biological and medical sciences Cell Division - drug effects Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - chemical synthesis Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacology Farnesyltranstransferase General aspects Heterocyclic Compounds - administration & dosage Heterocyclic Compounds - chemical synthesis Heterocyclic Compounds - chemistry Heterocyclic Compounds - pharmacology Humans Kinetics Medical sciences Mice Microsomes, Liver - drug effects Microsomes, Liver - metabolism Models, Molecular Molecular Conformation Pharmacology. Drug treatments Quinolones - administration & dosage Quinolones - chemical synthesis Quinolones - pharmacology Structure-Activity Relationship Triazoles - chemical synthesis Triazoles - chemistry Triazoles - pharmacology |
| title | 4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T15%3A44%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4-Methyl-1,2,4-triazol-3-yl%20heterocycle%20as%20an%20alternative%20to%20the%201-methylimidazol-5-yl%20moiety%20in%20the%20farnesyltransferase%20inhibitor%20ZARNESTRA&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry%20letters&rft.au=ANGIBAUD,%20Patrick&rft.date=2003-12-15&rft.volume=13&rft.issue=24&rft.spage=4361&rft.epage=4364&rft.pages=4361-4364&rft.issn=0960-894X&rft.eissn=1464-3405&rft_id=info:doi/10.1016/j.bmcl.2003.09.043&rft_dat=%3Cproquest_cross%3E71421760%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c329t-6cb7640e6699c6fa3851105ae6d0f651c8bd0d3bda1c443669f909d5551c8e693%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71421760&rft_id=info:pmid/14643326&rfr_iscdi=true |